Xianjing Chu

740 total citations · 2 hit papers
12 papers, 399 citations indexed

About

Xianjing Chu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Xianjing Chu has authored 12 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Xianjing Chu's work include Radiomics and Machine Learning in Medical Imaging (4 papers), Brain Metastases and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Xianjing Chu is often cited by papers focused on Radiomics and Machine Learning in Medical Imaging (4 papers), Brain Metastases and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Xianjing Chu collaborates with scholars based in China, United States and Canada. Xianjing Chu's co-authors include Rongrong Zhou, Wentao Tian, Ziqi Wang, Jing Zhang, Guilong Tanzhu, Jiaoyang Ning, Gang Xiao, Zhiyuan Liu, Gang Xiao and Lei Yang and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Xianjing Chu

12 papers receiving 395 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer stem cells: advances in knowledge and implications for cancer therapy

2024 191 citations Xianjing Chu, Wentao Tian et al. Signal Transduction and Targeted Therapy profile →
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

2023 114 citations Xianjing Chu, Wentao Tian et al. Molecular Cancer profile →

Peers

Xianjing Chu

ONCOL

MB

PRM

IMMUN

CR

Eriseld Krasniqi Italy

Yaqun Li China

Louqian Zhang China

Shengyu Wu China

Melinda E. Stack United States

Colin Snyder United States

Xinjian Huang China

Adrien Costantini France

Pan Chen China

Jelena Urosevic Spain

Eriseld Krasniqi Italy

Xianjing Chu

197 ×1.0

ONCOL

93 ×0.7

MB

95 ×0.9

PRM

59 ×0.7

IMMUN

99 ×1.6

CR

Citations per year, relative to Xianjing Chu Xianjing Chu (= 1×) peers Eriseld Krasniqi

Countries citing papers authored by Xianjing Chu

Since Specialization

Citations

This map shows the geographic impact of Xianjing Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianjing Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianjing Chu more than expected).

Fields of papers citing papers by Xianjing Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianjing Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianjing Chu. The network helps show where Xianjing Chu may publish in the future.

Co-authorship network of co-authors of Xianjing Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Xianjing Chu. A scholar is included among the top collaborators of Xianjing Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xianjing Chu. Xianjing Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Wang, Ziqi, et al.. (2025). A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer. Scientific Reports. 15(1). 7036–7036. 1 indexed citations

2.

Xiao, Gang, Guilong Tanzhu, Xianjing Chu, et al.. (2025). Predicting Survival Rates in Brain Metastases Patients from Non‐Small Cell Lung Cancer Using Radiomic Signatures Associated with Tumor Immune Heterogeneity. Advanced Science. 12(10). e2412590–e2412590. 3 indexed citations

3.

Chu, Xianjing, Gang Xiao, Jing Zhang, et al.. (2024). The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis. CNS Neuroscience & Therapeutics. 30(11). e70102–e70102. 1 indexed citations

4.

Chu, Xianjing, Wentao Tian, Jiaoyang Ning, & Rongrong Zhou. (2024). Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis. JNCI Journal of the National Cancer Institute. 116(10). 1571–1586. 6 indexed citations

5.

Chu, Xianjing, Wentao Tian, Jiaoyang Ning, et al.. (2024). Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduction and Targeted Therapy. 9(1). 170–170. 191 indexed citations breakdown →

6.

Liu, Zhiyuan, Xianjing Chu, Quan Cheng, et al.. (2023). MRI radiomics for brain metastasis sub-pathology classification from non-small cell lung cancer: a machine learning, multicenter study. Physical and Engineering Sciences in Medicine. 46(3). 1309–1320. 14 indexed citations

7.

Li, Yi, Xiaohua Dong, Guilong Tanzhu, et al.. (2023). The value of postoperative radiotherapy in thymoma patients with myasthenia gravis. Radiotherapy and Oncology. 183. 109644–109644. 4 indexed citations

8.

Chu, Xianjing, et al.. (2023). A multiomics approach-based prediction of radiation pneumonia in lung cancer patients: impact on survival outcome. Journal of Cancer Research and Clinical Oncology. 149(11). 8923–8934. 12 indexed citations

9.

Chu, Xianjing, et al.. (2023). Radiomics and deep learning models to differentiate lung adenosquamous carcinoma: A multicenter trial. iScience. 26(9). 107634–107634. 4 indexed citations

10.

Tian, Wentao, Xianjing Chu, Guilong Tanzhu, & Rongrong Zhou. (2023). Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis. Journal of Translational Medicine. 21(1). 244–244. 11 indexed citations

11.

Chu, Xianjing, Wentao Tian, Ziqi Wang, Jing Zhang, & Rongrong Zhou. (2023). Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. Molecular Cancer. 22(1). 93–93. 114 indexed citations breakdown →

12.

Chu, Xianjing, Gang Xiao, Zhiyuan Liu, et al.. (2022). The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Frontiers in Immunology. 13. 875488–875488. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact